moving from tirzepatide to semaglutide Switching Switching from Semaglutide to Tirzepatide:

Moving from 0.25 mg to 0.50 mg and from 0.50 mg to 1.0 mg represent the steepest relative dose jumps in the titration schedule (100% increases each time)

Understanding how to safely navigate social drinking while on this medication is essential for maintaining both your treatment plan and your well-being

Results of more studies testing the SGLT-2 inhibitor sotagliflozin in people with type 1 diabetes, continued to be encouraging: Sotagliflozin reduced A1C and body weight, lowered insulin doses, and caused fewer episodes of severe hypoglycemia compared to control groups

Bioavailability of subcutaneous semaglutide is approximately 89%, and protein binding exceeds 99%

Theyre looking for a clear path forward